2022 Annual Meeting Kick-off
We’ve officially kicked off #HTAi2022Utrecht and it was a JAM PACKED day with eight panel sessions; Symposia sessions led by F-Hoffman – La Roche LTD, and Merck and Co INC; a keynote address from Prof Marcel Levi; and a plenary dedicated to Adopting a Lifecycle Approach to HTA: Consequences in Priority Setting and International Collaboration.
You Better Believe It: Methodologies to Address Concerns in Using Real-World Evidence for Measures of Treatment Effectiveness (F. Hoffman-La Roche Ltd)
This session provided an overview of real-world evidence used in treatment effectiveness decision-making for HTA, and to understand concerns of bias regarding internal and external validity. Methodological approaches addressing these concerns, and results from studies applying these methods in oncology were discussed
Making Gene and Cell Therapies Reality for patients: How HTA and Novel Payment Solutions Play a Central Role (F. Hoffman- La Roche Ltd)
Diverse stakeholder perspectives explored the critical HTA role achieving the best patient outcomes, benefiting from cell and gene therapies. HTA adaptations of patient-centred priorities, challenges and solutions for these therapies, and how HTAs can ensure that the key stakeholders are engaged in ways that benefit patients, clinicians, policymakers, and innovation.
What does ‘Value’ mean in Cancer Policy & Practice? Interventions for Improved Patient Outcomes across Geographies (Merck Sharp & Dohme Corp)
Experts of the MSD Oncology Policy Grants Program explored insights from their research in Brazil, Mexico and the United Kingdom and discuss interventions they consider the most impactful to improve cancer outcomes. Together with experts from advocacy and government, they debated the dimensions of ‘value’: How can we measure it? How can we use it for evidence-based policy and practice?
Adopting a Lifecycle Approach in HTA: Consequences for Priority-Setting and International Collaboration
HTA has recently been defined as “a multidisciplinary process that uses explicit methods to determine the value of a health technology at different points in its lifecycle. The purpose is to inform decision-making in order to promote an equitable, efficient, and high-quality health system” (O’Rourke, Oortwijn and Schuller, Int J Technol Assess Health Care 2020; 36: 187 – 190).
Adopting such a lifecycle approach in HTA has a number of potentially far-reaching consequences. Rather than a one-off exercise to critically appraise and synthesize the best available evidence to support market access and coverage decisions, it involves several tasks and requirements which continuously need attention. Central, but not exclusive, is the careful monitoring of novel technological developments, the anticipation of their potential impact, and keeping track of their evolution, especially in terms of gaining or losing value as the result of (parallel) technological, epidemiological, economic, organizational and cultural developments.
Visit our Exhibition Hall at any time during the Annual meeting! It’s an excellent opportunity to search the list of exhibitors, pick brochures, and much more!
Additionally, be sure to visit the Annual Meeting oral and poster presentation gallery, where you can browse and search for presentations that interest you.
On Demand Coming Soon
If you missed the Opening Ceremony, Keynote Speaker, Prof. Marcel Levi’s welcome address, or Plenary One, we have good news: you will be able to watch the presentations and discussions on-demand in the coming weeks – stay tuned!
See What Your Colleagues Are Saying
Today was a big event on Twitter! Delegates had fun posing questions, sharing learning moments, and promoting their Panel, Oral, and Poster presentations. The HTAi Annual Meeting team is sharing and commenting on posts throughout the conference. Search the official event hashtag, #HTAi2022Utrecht, or visit HTAi on Twitter, @HTAiorg, to read what everyone was talking about.